Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-06-20T20:30:12.486Z Has data issue: false hasContentIssue false

Use of intravenous valproate in acute manic: about a clinical case

Published online by Cambridge University Press:  01 September 2022

M. Suárez Gómez*
Affiliation:
ULSBA, Psychiatry, Beja, Portugal
A. Suárez Gómez
Affiliation:
UCC, Community Health, Borba, Portugal
P. Rodrigues
Affiliation:
ULSBA, Psychiatry, Beja, Portugal
S.S. Sánchez Rus
Affiliation:
Hospital Neuropsiquiátrico de Jaén, Psychiatry, Jaén, Spain
A. Matos-Pires
Affiliation:
ULSBA, Psychiatry, Beja, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Acute mania can have behavioral effects such as agitation, being a frequent cause of presentation in the emergency department. Pharmacological treatments include mood stabilizers and atypical antipsychotics. Valproate is an effective drug. However, the intravenous formulation is relegated to other pathologies, such as epilepsy.

Objectives

The objective was to review the use of intravenous valproate in acute mania in the literature and present its use through a clinical case.

Methods

A clinical case using intravenous valproate to treat an episode of acute mania is described and the scientific literature of the last 5 years is reviewed.

Results

A 43-year-old patient attended the emergency department with a diagnosis of bipolar disorder type I in manic episode with agitation, rejection of oral medication, brought in by the police due to risk of aggression against family members, who reported that the patient had stopped taking her usual medication with valproate 500 mg / 24h and quetiapine 200 mg / 24h threemonths ago. Due to the possibility of having intravenous valproate, it was decided to administer 300 mg intravenously, as well as haloperidol 5 mg intravenously, and hospitalization was decided. The patient had a favorable evolution, with no side effects to the medication, and oral treatment was started after 8 hours, with a good response. In the literature there are few studies in this regard, although the most of them approved the use of valproate as a loading dose in acute mania.

Conclusions

Intravenous valproate is an effective, safe, and tolerated treatment in acute mania. More studies are needed to collect precise information.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.